Provasopressin antagonists and uses thereof
AssigneeWoomera Therapeutics
InventorsWilliam G. North, Roy H. L. Pang
Life of this patent
Estimating the term…
Abstract
Provided herein are pro-VP antagonists, such as antibodies and antigen-binding portions thereof specific for pro-VP, for identifying and targeting expressing cancer cells. Applicants additionally provide methods of using said compositions, for example to image cancer cells in vivo and in biological samples. The compositions may also be used for treating patients suffering from a provasopressin-expressing cancer. Provasopressin-expressing cancers include neuroendocrine cancer, pancreatic cancer, and prostate cancer.
Claims18
A method of treating a provasopressin-expres sing (pro-VP-expressing) cancer, comprising administering, to a patient in need thereof, a therapeutically effective amount of a provasopressin-binding antibody or an antigen-binding portion thereof specific for the C-terminal 18-amino-acid VAG region of provasopressin (pro-VP), wherein the provasopressin-binding antibody is MAG-1, a humanized antibody thereof, or a chimeric antibody thereof, and wherein the cancer is a neuroendocrine cancer or a pancreatic cancer.
A method of killing or inhibiting the growth of a provasopressin-expressing cancer cell, comprising contacting the provasopressin-expressing cancer cell with a provasopressin-binding antibody or an antigen-binding portion thereof specific for the C-terminal 18-amino-acid VAG region of provasopressin (pro-VP), wherein the provasopressin-binding antibody is MAG-1, a humanized antibody thereof, or a chimeric antibody thereof, and wherein the provasopressin-expressing cancer cell is from a neuroendocrine cancer or a pancreatic cancer.
Dependencies are inferred from the claim text.